FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APP	ROVAL					
OMB Number: 3235-028						
Estimated average burden						
hours per response:	0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* FREEMAN KEVIN D (Last) (First) (Middle)					2. Issuer Name and Ticker or Trading Symbol GALECTIN THERAPEUTICS INC GALT									ck all applic Directo	able)	g Pers	10% Ow Other (s below)	vner		
G, C 011		HERAPEUTICS			03/2			Trans	saction (Moi	ith/L	ay/Year)									
4960 PE.	ACHTREE	INDUSTRIAL	BLVD., ST	E 240	4. If a	If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable						
(Street) NORCR	OSS G	A	30071									X Form filed by One Reporting Person Form filed by More than One Reporting Person								
(City)	(S	tate)	(Zip)																	
		Tak	le I - Non	-Deriva	ative	Se	curities	s Ac	quired, [isp	osed o	f, or Be	nefic	ially	Owned					
Date			2. Transa Date (Month/D		Execution Date,		Transaction Disposed Code (Instr. 5)		ities Acquired (A) o d Of (D) (Instr. 3, 4 a		and Securitie Beneficia		es Formally (D) (Following (I) (II)		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
					Code V Amount (A) or (D)				Pric	ce	Transaction(s) (Instr. 3 and 4)				(111311.4)					
		•	Table II - [uired, Di s, options						Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	ate, Tr	ransaction of lode (Instr. Derivative (6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and A of Securities Underlying Derivative Se (Instr. 3 and 4			ies g Secur		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e S Ily	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)				
				C	ode \	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amou or Numb of Share	oer						
Stock																				
option (right to buy) ⁽¹⁾	\$2.11	03/25/2021			A		40,000		(2)	0:	3/25/2031	Common Stock	40,0	00	\$0.00	40,000	0	D		

Explanation of Responses:

- 1. The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan.
- 2. Such options vest 100% on March 31, 2022.
- 3. Such options vest when (i) the Company has received the interim results of its NAVIGATE clinical trial and (ii) makes a public announcement that it has received the interim results.

Remarks:

(1) The reporting person is president and director of Ed Uihlein Family Foundation, a not-for-profit corporation. The reporting person has no pecuniary interest in the shares, however, he shares voting and dispositive power over the shares and, therefore, remains the beneficial owner of the shares solely for the purposes of Section 13(d) of the Securities Exchange Act of 1934.

/s/ Jack W. Callicutt, by power 03/29/2021 of attorney

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.